Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 421 to 435 of 711 results for medication

  1. Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

    Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.

  2. Digital platforms recommended to help people manage their asthma

    People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition, states our draft guidance published today.

  3. Borderline personality disorder: recognition and management (CG78)

    This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.

  4. NICE says paperclip-sized sensor could help thousands monitor heart condition from home

    A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before they become emergencies, NICE has said.

  5. Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting (HTG415)

    Evidence-based recommendations on transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting in adults. This involves reversing blood flow away from the brain and filtering the blood to remove any debris.

  6. Caesarean birth (NG192)

    This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.

  7. Percutaneous electrical nerve stimulation for refractory neuropathic pain (HTG308)

    Evidence-based recommendations on percutaneous electrical nerve stimulation for refractory neuropathic pain. This involves inserting electrode needles underneath the skin connected to a stimulator device.

  8. Carfilzomib for previously treated multiple myeloma (TA657)

    Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.

  9. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

  10. LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)

    NICE has developed a medtech innovation briefing (MIB) on LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands

  11. Suspected neurological conditions: recognition and referral (QS198)

    This quality standard covers assessing and referring children (under 16) and adults (16 and over) who have symptoms or signs associated with neurological conditions. It describes high-quality care in priority areas for improvement.

  12. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  13. Cirrhosis in over 16s: assessment and management (NG50)

    This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.

  14. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

    Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.